Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report

BACKGROUND: Nivolumab is an immune checkpoint inhibitor that blocks inhibitors of T-cell activation and blunts antitumor immunity and is used in the treatment of various cancers. However, immune checkpoint inhibitors have immune-related adverse effects on various organs due to promoting T-cell activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Saishu, Yumi, Yoshida, Takuya, Seino, Yusuke, Nomura, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842808/
https://www.ncbi.nlm.nih.gov/pubmed/35152911
http://dx.doi.org/10.1186/s13256-022-03286-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842808/
https://www.ncbi.nlm.nih.gov/pubmed/35152911
http://dx.doi.org/10.1186/s13256-022-03286-x

Ejemplares similares